Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could popular diabetes drugs boost cancer survival? new study investigates

NCT ID NCT07513259

Knowledge-focused Sponsor: Chung Shan Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This study analyzed health records of over 200,000 adults with obesity and type 2 diabetes to see if taking GLP-1 drugs (like Ozempic) before a cancer diagnosis is linked to better survival and fewer complications after cancer. The researchers compared GLP-1 users to those on other diabetes medications. Because this is an observational study, it can only suggest possible connections, not prove that the drugs cause better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonists (e.g., semaglutide, liraglutide)
What this could lead to
If the study finds a link, it could suggest that GLP-1 drugs might improve survival after cancer in people with obesity and diabetes, guiding future research.
What could go wrong
This is an observational study, not a controlled trial, so it can only show associations, not cause and effect. Results may be influenced by other factors and need confirmation in clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

203,424 people

The number who actually took part.

Started

Jan 2018

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults will be selected from the TriNetX US Collaborative Network, a distributed database of de-identified electronic health records contributed by participating healthcare organizations across multiple clinical systems and practice settings. The study population consists of adults with obesity and type 2 diabetes who received routine clinical care in this network and were identified through diagnosis records, body mass index data, and medication prescribing data. The overall study population was classified into two mutually exclusive cohorts according to pre-diagnosis GLP-1 receptor agonist use: participants with pre-diagnosis GLP-1 receptor agonist use and participants without pre-diagnosis GLP-1 receptor agonist use. Comparator-specific propensity score-matched cohorts for GLP-1 RA versus SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, metformin, and usual care were defined within this source population for prespecified pairwise outcome analyses.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * BMI ≥27 kg/m2, or diagnosis codes consistent with obesity * Type 2 diabetes mellitus * Initiation of a glucose-lowering medication before obesity-associated cancer diagnosis * Incident obesity-associated cancer diagnosed after medication initiation * No dispensing of the study drug class during the 6-month washout period before the first qualifying prescription Exclusion Criteria: * Type 1 diabetes mellitus, Other specified diabetes types that are not type 2 diabetes * Human immunodeficiency virus infection * End-stage renal disease * Prior bariatric surgery * Prior organ transplantation * Transplant-related complications * Any use of tirzepatide before cohort entry

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Neoplasms Obesity / overweight

Contacts and locations

Locations

  • Chung Shan Medical University Hospital

    Taichung, Taichung City, 402, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.